News Focus
News Focus
Followers 50
Posts 9236
Boards Moderated 0
Alias Born 01/13/2007

Re: XenaLives post# 8963

Sunday, 03/24/2019 1:06:01 PM

Sunday, March 24, 2019 1:06:01 PM

Post# of 21574
You mean the same way that Sigma-1 Pridopidine failed for Teva after early success?

When I look at a potential drug I try to find reasons it might fail, that's why I'm so informed about several of these drugs. It doesn't take long to find S-1 or M-1 problems as research advances.

Or this failure in Japan?
"A Japanese drug company, Toyama Chemical, is developing an Alzheimer's drug with the same sigma-1 receptor mechanism of action as Anavex's Anavex 2-73. Two years ago, Toyama reported results from a randomized, placebo-controlled phase IIa study enrolling 370 Alzheimer's patients.

The results were disappointing: Toyama's drug, T-817MA, failed to demonstrate a statistically significant improvement in memory, cognition or activities of daily living compared to placebo during the 52 weeks of the study."
https://seekingalpha.com/article/4074451-anavex-life-sciences-5-reasons-short?page=3
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TAOX News